Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort studyEmilio Portaccio, Maria Pia Amato, Angelo Bellinvia et al.|Brain|2022Cited by 158
A Stage-Based Approach to Therapy in Parkinson’s DiseaseClaudia Carrarini, Laura Bonanni, Marianna Gabriella Rispoli et al.|Biomolecules|2019Cited by 55
The Pharmacology of Visual Hallucinations in SynucleinopathiesMirella Russo, Marco Onofrj, Claudia Carrarini et al.|Frontiers in Pharmacology|2019Cited by 55
The effectiveness of natalizumab vs fingolimod–A comparison of international registry studiesJohanna Balslev Andersen, Gilles Edan, Sifat Sharmin et al.|Multiple Sclerosis and Related Disorders|2021Cited by 12
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Éric Berger, Mathilde Lefort et al.|CNS Drugs|2021Cited by 12